Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
How must databases adapt to generative AI, and how should databases be integrated with large language models (LLMs)? These are questions that Sailesh Krishnamurthy has grappled with for several years ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
What if your AI agent could not only answer your questions but also truly understand them, navigating complex queries with precision and speed? While the rise of vector search has transformed how AI ...
Forbes contributors publish independent expert analyses and insights. We set an example for a better future via education and research. The possible shift back to entirely in-person work has sparked a ...
Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
In most enterprises, data access still feels like a locked room with SQL as the only key. Business teams depend on data engineers for every report, dashboard, or metric tweak. Even in the age of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results